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In vertebrate development, a prominent feature of several cell lineages is the coupling of cell cycle regulation
with terminal differentiation. We have investigated the basis of this relationship in the skeletal muscle lineage
by studying the effects of the proliferation-associated regulator, c-myc, on the differentiation of MyoD-initiated
myoblasts. Transient cotransfection assays in NIH 3T3 cells using MyoD and c-myc expression vectors
demonstrated c-myc suppression of MyoD-initiated differentiation. A stable cell system was also developed in
which MyoD expression was constitutive, while myc levels could be elevated conditionally. Induction of this
conditional c-myc suppressed myogenesis effectively, even in the presence of MyoD. c-myc suppression also
prevented up-regulation of a relative of MyoD, myogenin, which is normally expressed at the onset of
differentiation in all muscle cell lines examined and may be essential for differentiation. Additional experiments
tested whether failure to differentiate in the presence of myc could be overcome by providing myogenin
ectopically. Cotransfection of c-myc with myogenin, MyoD, or a mixture of myogenin and MyoD showed that
neither myogenin alone nor myogenin plus MyoD together could bypass the c-myc block. The effects of c-myc
were further dissected by showing that c-myc can inhibit differentiation independently of Id, a negative
regulator of muscle differentiation. These results lead us to propose that c-myc and Id constitute independent
negative regulators of muscle differentiation, while myogenin and any of the other three related myogenic
factors (MyoD, Myf-5, and MRF4/herculin/Myf-6) act as positive regulators.
During skeletal muscle development, multipotential pre-
cursor cells progress through a determined myoblast stage
before differentiating to become myocytes. While precursors
and myoblasts proliferate extensively, withdrawal from the
cell cycle is required for differentiation (13). The onset of
differentiation is characterized by the expression of genes
that code for muscle-specific enzymes, contractile proteins,
and receptors that are not expressed in myoblasts (reviewed
in reference 48). The determination step that establishes a
cell as a myoblast can be forced in many fibroblast cell lines
by expression of any one of the four members of the MyoD
family of myogenic regulatory genes. This family (reviewed
in reference 42) includes genes encoding MyoD (17, 54),
myogenin (20, 59), and Myf-5 (7) and the rat gene encoding
MRF4 (47) which is called herculin in mice (37) and Myf-6 in
humans (6). All share a highly similar 57-amino-acid B-HLH
domain characterized by a strongly basic region in the amino
portion followed by a potential helix-loop-helix (HLH) struc-
ture (40). Similar domains are also found in an extended
family of nuclear proteins (reviewed in reference 31). In
vertebrates, these include the myc family of protooncogenes
(reviewed in reference 14), twist (28), achaete-scute (29), and
the E12 and E47 proteins, first identified as binding to the
immunoglobulin K-chain enhancer (40).
In vitro studies of DNA binding and protein-protein inter-
actions, together with mutagenesis studies, show that the
B-HLH domain is functionally important (9, 16, 34, 41). The
HLH portion mediates protein-protein interactions between
molecules to yield homo- or hetero-oligomers. Dimers or
higher order oligomers are the molecular species capable of
binding to DNA in a sequence-specific fashion, and such
binding is dependent on the presence of an intact basic
region in each monomer. Some mutants with mutations in
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the basic region of MyoD which do bind DNA in vitro do not
activate muscle-specific gene expression in vivo, suggesting
that the basic region plays a complex role in gene activation
(16).
Further support for the roles of the basic and HLH regions
in producing active DNA-binding proteins comes from the
nature of the protein Id (2). Id contains an HLH domain but
not an adjacent basic region. It can associate in vitro with
MyoD, E12, and E47 and inhibit their binding to DNA. In
vivo, overexpression of Id inhibits the trans-activation of the
muscle creatine kinase (MCK) enhancer upon cotransfection
with MyoD. Thus, Id, which is widely expressed, appears to
negatively regulate the differentiation functions of tissue-
specific B-HLH complexes by sequestering components of
such complexes in inactive hetero-oligomers (2).
The structural similarity of the MyoD family of regulators
with the myc family of proto-oncogenes is interesting be-
cause c-myc is strongly implicated in the control of cell
proliferation in several different cell lineages, including
muscle (30, 51). During myogenesis, c-myc is expressed in
proliferating myoblasts, but myc mRNA and protein levels
drop substantially when these cells withdraw from the cell
cycle and differentiate (22, 51). myc is further implicated in
the proliferation-differentiation switch by the fact that differ-
entiation-defective derivatives of some myoblast cell lines
fail to down-regulate c-myc expression (51). Other studies
show that ectopic myc expression can interfere with myo-
blast differentiation (18, 24, 50). Conversely, MyoD has
recently been shown to inhibit the serum-induced progres-
sion of quiescent cells into S phase (iSa, 52). Considered
together, the pattern of myc expression, its sequence simi-
larity to MyoD, its nuclear localization, and the apparent
effects of ectopic expression make attractive the possibility
that myc and MyoD play pivotal and opposing roles in
controlling the differentiation decision.
In this study we show that c-myc can inhibit the differen-
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tiation of cells made myogenic by transfection of a gene
encoding MyoD in both transient and stable assays of NIH
3T3 cells. An important virtue of this system is the ability to
study the activities of ectopic MyoD, myogenin, and c-myc
in the absence of Myf-5, herculin, and endogenous MyoD, as
these genes are not activated in these cells by MyoD (37, 55).
Our results show that MyoD and myogenin are not sufficient,
acting alone or together, to drive muscle differentiation in
the presence of high levels of c-myc. Moreover, the myc
suppression can function independently of Id activity, sug-
gesting that there are at least two negative regulators nor-
mally expressed in undifferentiated myoblasts that can pre-
vent differentiation.
MATERUILS AND METHODS
Expression vector constructions. The MT-myc gene in 3T3
MT-myc cells contains the metallothionein-I promoter
(EcoRI to BglII, [38]) fused to a c-myc minigene containing
the last 33 nucleotides (nt) of the first intron (from the XbaI
site), exons 2 and 3 (without intron 2) up to the Nsil site (3),
and the metallothionein-I polyadenylation signal sequence.
The MyoD expression vehicle pEMclls was a gift from
Andrew Lassar (17). Simian virus 40 (SV40)-promoted genes
used in the transient cotransfections were all constructed in
pECE (21), a 2.9-kb vector which contains the SV40 early
promoter and T antigen polyadenylation signal sequences
flanking a multiple cloning site. pSVclls contains the 1.8-kb
EcoRI fragment (MyoD cDNA) from pEMclls cloned into
the EcoRI site of pECE. pSVmyc contains the 1.4-kb
XbaI-to-XhoI fragment of c-myc (from MT-myc) cloned into
the XbaI site of pECE via a three-step ligate-blunt-ligate
procedure. pSVrGEN contains rat myogenin cDNA (a gift
from Woody Wright) as a 1.5-kb EcoRI fragment from
BS-il, which contains the cDNA (59), cloned into the EcoRI
site of pECE. Standard procedures were used for all manip-
ulations (36).
Cell culture and DNA transfections. NIH 3T3 cells ob-
tained from the American Type Culture Collection were
grown in Dulbecco's Modified Eagle's Medium (DMEM)
(Flow)-10%o calf serum (GIBCO or Irvine Scientific) supple-
mented with penicillin (10 U/ml) and streptomycin (10 p,g/ml)
(Irvine Scientific). 3T3 MT-myc cells were grown in DMEM-
10% fetal bovine serum (FBS) (HyClone). Prior to stable
transfection with the MyoD expression vehicle pEMclls,
NIH 3T3 cells and 3T3 MT-myc cells were plated on
10-cm-diameter gelatin-coated plates in DMEM-109o FBS.
They were transfected by calcium phosphate coprecipitation
(57) with 10 ,ug of pEMclls-1 p.g of pY3 (which confers
resistance to hygromycin B [4])-5 ,ug of sheared L cell DNA
(as carrier). After 12 h, cells were treated with 15% glycerol
in DMEM for 2 min, rinsed with phosphate-buffered saline,
and fed DMEM-15% FBS. Twenty-four hours later the
medium was supplemented with 200 jig of hygromycin B per
ml (Calbiochem). After 10 days, surviving colonies were fed
differentiation medium (DMEM, 2% horse serum [Flow
Labs], and 8 ,ug of insulin per ml [GIBCO]). Colonies which
began to show morphological changes characteristic of my-
ocytes were picked after 36 to 48 h and expanded in
DMEM-15% FBS.
NIH 3T3 cells used in transient transfections were plated
on uncoated dishes in DMEM-10% calf serum. Transfec-
tions were performed as described above, but the glycerol
shock was omitted. Plasmid mixtures are described in the
figure legends. Forty-eight hours after transfection, plates
were fed DMEM-2% horse serum-2 ,ug of insulin per ml to
induce differentiation. Three days later plates were fixed and
immunostained for the myosin heavy chain (MHC) with
horseradish peroxidase as described by Rhodes and Koniec-
zny (47) by using the monoclonal antibody MF20 (1) and
Amersham secondary reagents.
RNA isolation and analysis. RNAs were prepared by the
method of Chomczynski and Sacchi (12) from cells on
15-cm-diameter dishes by using 4 ml of guanidinium solu-
tion. Relevant transcripts were analyzed by ribonuclease
protection assays. Hybridizations were done in 30 >i± of 80%o
deionized formamide-40 mM PIPES (pH 6.4) [piperazine-
N,N'-bis(2-ethanesulfonic acid)]-l mM EDTA-400 mM
NaCl under mineral oil at 50°C for 12 h by using 2.5 or 5 p.g
of total RNA and 5 x 109 radiolabeled probe molecules per
hybridization. Unhybridized probes were digested by adding
300 ,ul of 10 mM Tris (pH 7.5)-S5 mM EDTA-300 mM NaCl-1
U of RNase Ti (Bethesda Research Laboratories) per p.1. In
addition, 0.36 ng of RNase A (Sigma) per ml was used for
human ly-actin and Id probe digestions. Ribonucleases were
digested with proteinase K (Boehringer Mannheim), samples
were extracted with phenol-chloroform-isoamyl alcohol (25:
24:1), and protected probes were isopropanol precipitated
with 30 ,ug of yeast type III RNA (Sigma) as a carrier. Pellets
were dissolved in 80%o formamide and electrophoresed
through 8% denaturing polyacrylamide gels, which were
exposed to Kodak XAR-5 film at -70°C with an intensifying
screen.
Probes for ribonuclease protections. Radiolabeled ribo-
probes were synthesized by using SP6 (Promega), T3, or T7
(Pharmacia or US Biochemical Corp.) RNA polymerase and
[a-32P]CTP or UTP (Amersham or New England Nuclear).
pSP6 g-actin contains a fragment of the human -y-actin gene
(26) in pSP64. When cut with Hinfl and transcribed with SP6
RNA polymerase, the resulting 145-nt probe protects a 65-nt
frnaent of mouse y-actin RNA (23). The MyoD probe BH8
contains the -600-bp HindIl-to-BamHI fragment ofpEMclls
inserted into Bluescript KS' (Stratagene). BH8 is cut with StyI
(nt 1692 in reference 17) and transcribed with T7 RNA poly-
merase to make a probe that produces a 116-nt protected
fragment from transcripts off pEMclls and a 92-nt fragment
from transcripts off the endogenous MyoD gene. The mouse
myc probe used extends from the EcoRV site in the second
exon to the XbaI site in the first intron and was transcribed with
T3 RNA polymerase. This probe distinguishes between tran-
scripts from the MT-myc gene and the endogenous gene. The
mouse myogenin plasmid SRmyo8 contains the 224-bp EcoPI-
to-SmaI fragment (5' end in reference 20) inserted into EcoRI-
and SmaI-cut Bluescript II KS'. This plasmid is cut with Styl
(nt 35 of myogenin) and transcribed with T7 RNA polymerase.
The Id plasmid pMH18AR (2) was cut with DdeI at nt 817 and
transcribed with T7 RNA polymerase to make a 174-nt probe,
110 nt of which is protected by Id RNA.
RESULTS
myc inhibits differentiation initiated by MyoD in transient
cotransfection assays. To test the effects of c-myc on MyoD-
initiated myogenesis, we performed a series of transient
cotransfections in which the absolute amount of MyoD was
held constant and the amount of myc was varied. To avoid
difficulties stemming from differences in promoter strength,
both genes were placed under the control of the constitutive
SV40 early promoter in the plasmid pECE (21). Also, to
guard against artifactual effects due to competition for fac-
tors driving the SV40 promoter, these transfection mixtures
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FIG. 1. Transient inhibition of MyoD-mediated myogenesis by
c-myc. These experiments show that in transient cotransfections,
differentiation is most efficient at low molar ratios of myc to MyoD
plasmids and is least efficient at higher ratios. NIH 3T3 cells were
transfected in two separate experiments (represented by hatched
and black bars) using different myc plasmid preparations. DNA
mixtures contained 5 ,ug of pSVclls (SV40 early promoter-driven
MyoD), enough of the myc plasmid pSVmyc (SV40 early promoter-
driven myc) to make the indicated myc/MyoD ratios, enough pECE
(SV40 promoter alone) to equalize the molar amount of SV40
promoter per plate, and either 1 jig of pY3, 1.5 Rg ofpSV2CAT, plus
enough sheared L cell DNA to make 25.8 .g of DNA per 10-cm
plate (for hatched bars) or 2 ,g of pSV2CAT plus enough pT7T3-18
(Bethesda Research Laboratories) to make 25.3 ,zg ofDNA per plate
(for black bars). Chloramphenicol acetyltransferase activity was not
significantly variable from point to point (data not shown). For the
experiment represented by the hatched bars, 20 fields at 25x power
on each of two plates were counted and averaged per point; 100
represents 1,960 MHC-positive cells. For the experiment repre-
sented by the black bars, 25 fields on one plate were counted per
point; 100 represents 12,722 MHC-positive cells.
all contained the requisite amount of pECE vector such that
the total molar amount of SV40 promoter in each transfec-
tion mixture was identical. NIH 3T3 cells were transfected
with these mixtures along with the SV40-promoted bacterial
chloramphenicol acetyltransferase gene (pSV2CAT) to con-
trol for significant transfection efficiency differences from
plate to plate. After 3 to 4 days in differentiation medium, the
cells were fixed and the number of MHC-positive cells were
counted after immunostaining. The results of two such
experiments (hatched and black bars) are shown in Fig. 1. As
MyoD is held constant and c-myc is increased, the number of
differentiated muscle cells diminishes by up to 90%. These
results suggest that c-myc has a strong inhibitory effect on
the ability of MyoD to promote differentiation in NIH 3T3
cells. By comparison with prior observations of retroviral
inhibition of primary myoblast differentiation (24) or trans-
fections of naturally occurring myoblast cell lines (e.g.,
reference 18) in which the complement of muscle regulators
already being expressed is unknown, the results in this
system specifically show inhibition of MyoD-initiated differ-
entiation.
myc overexpression inhibits MyoD-initiated differentiation
in stable transfectants. There are likely to be important
intermediate steps between expression of ectopic MyoD and
activation of muscle-specific genes. Otherwise, any cell
which expresses MyoD would become myogenic; but this is
not the case (56). However, while the transient assays show
that c-myc inhibits MyoD-initiated myogenesis, the small
fraction of cells which actually take up and express DNA are
not suitable for further characterization of the regulatory
pathway. We therefore constructed a set of NIH 3T3-based
cell lines that are myogenic because of constitutive expres-
sion of a transfected MyoD cDNA. Some of these lines also
carry a c-myc gene under the control of the mouse metal-
lothionein-I promoter (MT-myc gene) which can be induced
up to 10-fold above endogenous myc protein levels by
supplementing the culture medium with zinc sulfate (54a).
However, these MT-myc cells do not appear to be growth
transformed, as they do not form foci in culture or tumors in
nude mice, even when treated with zinc. A useful feature of
conditional myc expression is that it helps to ensure that the
phenotypic effects observed are attributable to transient
overexpression of c-myc and not to long-term secondary
effects of chronic myc expression or to the emergence of
differentiation-defective derivatives, a possible factor in
prior studies of the effects of myc on myogenesis. Myogenic
derivatives of these MT-myc cells and of the parental NIH
3T3 cells were made in parallel transfections by using the
MyoD expression vector pEMclls (17). The myogenic po-
tential of MyoD-transfected cell clones was evaluated by
immunostaining for expression of MHC after cultivation for
several days in a mitogen-poor differentiation medium. Sev-
eral independent myogenic transformants in both 3T3 and
3T3 MT-myc backgrounds were subcloned, and the most
myogenic of these were chosen for further study.
MyoD myoblasts carrying the zinc-inducible MT-myc
gene (MT-myc/MyoDl cells) differentiate in the absence of
added metal, but differentiation is suppressed in the pres-
ence of zinc. MyoD myoblasts lacking the metal-inducible
myc gene (MyoDl cells) are unaffected by zinc and differ-
entiate to similar extents in the presence or absence of added
metal. This result is visualized by the immunocytochemical
stain for MHC shown in Fig. 2A, and a quantitation is
presented in Fig. 2B. Differentiated cells were scored by
counting cells that stain positive for MHC; similar results
have been obtained by immunostaining for MCK and by
quantitating MCK RNA levels (data not shown). Differenti-
ation was not completely suppressed when myc was in-
duced, a result which is expected if the quantity of c-myc
expressed is crucial for suppression, since immunostaining
for c-myc has shown that it does not accumulate to uniformly
high steady-state levels in all cells of the MT-myc line (54a).
We conclude that in these cells, differentiation is specifically
suppressed by the induction of MT-myc expression.
myc suppresses differentiation even in the presence of
MyoD. How are the differentiation phenotypes in these
experiments related to the levels of MyoD and myc expres-
sion? To begin to answer this question, the levels of myc and
MyoD transcripts were measured by a ribonuclease protec-
tion assay. Results shown in Fig. 3 confirm that in the
MT-myc/MyoD line, myc transcripts from the transgene
accumulate to significantly elevated levels in the presence of
added zinc (Fig. 3; in the 3.5-h exposure of the myc probe,
compare lane 1 with 2 and lane 3 with 4 and in the longer
exposure, compare lane 5 with 6). Lower myc levels are
observed in the absence of added zinc when cells differen-
tiated well, while the elevated myc levels are from cells that
failed to differentiate efficiently (as in Fig. 2). It is relevant
that by the criteria of appearance, adherence to the plate,
yield of RNA, and level of expression of cytoplasmic -y-actin
RNA (Fig. 3), all cells seemed equally healthy under all
MOL. CELL. BIOL.
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FIG. 2. Muscle differentiation suppressed by zinc-dependent
induction of c-myc in MT-myc/MyoDl cells but not in control
MyoDl cells. (A) Immunocytochemical staining for the presence of
muscle MHC in MyoDl cells and in MT-myc/MyoDl cells. Differ-
entiated cells stain brown, while cells that do not express MHC are
counterstained light violet with hematoxylin. Cells were cultured for
6 days in a mitogen-poor differentiation medium (DMEM containing
1% horse serum and 5 ,ug of insulin per ml) with the concentration
of zinc sulfate indicated. Zinc induces expression of myc from the
MT-myc transgene in 3T3 MT-myc cells. Note that cell fusion does
not occur in differentiated MyoDl or MT-myc/MyoDl cells. (B)
Quantitation of an experiment similar to that described for panel A.
Cells were cultured in differentiation medium with 50 ,uM (black
bars) or no (hatched bars) zinc sulfate for -6 days. Note that
differentiation is suppressed in zinc-treated MT-myc cells, while
zinc has no inhibitory effect on differentiation of MyoDl cells
lacking the MT-myc gene. Additionally, zinc had no significant
effect on the average number of cells present in the random
microscopic fields which were assayed.
conditions tested. Also, changes in myc RNA levels in 3T3
and MT-myc 3T3 cells have been found to reflect similar
changes in myc protein levels (54a), although it remains
possible that there is some additional control at the transla-
tional level for myc or for MyoD (54) in these cells.
Levels of MyoD expression were measured, and they
revealed that under all conditions transgene MyoD was
expressed. MyoDl control cells expressed lower levels of
MyoD than did MT-myc/MyoDl cells, yet both cell lines
differentiated well (unless myc was elevated). The probe
used to measure MyoD discriminated between the transgene
(shown in Fig. 3) and endogenous MyoD. In both cell lines
the endogenous MyoD gene was silent (37) and therefore
made no contribution to overall MyoD levels. In the MT-
myc/MyoDl line, levels of MyoD decreased modestly at
later time points in the presence of metal (Fig. 3; for the
MyoD probe, compare lane 3 with 4 and lane 5 with 6).
However, this decrease is not likely to be the direct cause for
inhibition of differentiation, because even the reduced MyoD
levels substantially exceed amounts that are sufficient for
differentiation in the control MyoDl cell line (Fig. 3, lanes 7
through 12).
These data, taken together with the levels of myc ex-
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FIG. 4. Ribonuclease protection assays for myogenin RNA. The
RNA samples used in Fig. 3 were assayed for expression of
myogenin. The results show that differentiated cells express myo-
genin, but those inhibited by c-myc from differentiating do not (lanes
4 and 6). The amount of RNA used was 2.5 ,ug for each lane.
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FIG. 3. Ribonuclease protection assays for myc and MyoD
RNAs. Total RNA was extracted from MT-myc/MyoDl and control
MyoDl cells were cultured as indicated. RNAs in lanes 1, 2, 7, and
8 are from cells harvested 3 h after feeding with rich medium with or
without zinc sulfate (as indicated by + or -). RNAs in lanes 4 and
6 are from cells inhibited from differentiating, while lanes 3, 5, and
9 through 12 contain RNAs from differentiated cells, as assayed by
MHC and MCK expression (data not shown). The relevant bands
have been excised from large gels. A probe for cytoplasmic y-actin
(23) was used to verify the quality and amount of RNA for each
timepoint, which was 2.5 p.g (determined spectrophotometrically).
Note the two different exposures for myc as indicated.
place some informative constraints on how c-myc and MyoD
might be acting on the differentiation decision. Comparison
of the absolute amount of total c-myc RNA in each of the
two cell lines in the absence of zinc (Fig. 3, lanes 1, 3, and 5
compared with lanes 7, 9, and 11, respectively, of the
2.5-day exposure of the myc probe) shows that the two
express significantly different levels. c-myc levels that are
permissive for differentiation in MT-myc/MyoDl cells ex-
ceed those expressed in rapidly proliferating MyoDl cells
(e.g., lane 7) and other myoblast cell lines (data not shown).
Nevertheless, when the MT-myc gene is induced with zinc,
myc levels rise high enough-perhaps over a threshold-to
suppress differentiation even in the presence of abundant
amounts of MyoD (Fig. 3, lanes 4 and 6). In this context, the
observed decrease in MyoD RNA levels from lane 3 to 4 and
lane 5 to 6 associated with added zinc may serve to lower
any threshold over which c-myc levels must rise to efficiently
suppress MyoD-dependent differentiation. Therefore, we
conclude that c-myc effects on myogenesis depend on the
quantity of c-myc, not its mere presence or absence. The
amount required for suppression of differentiation in these
cells is high, exceeding levels that characterize myoblasts
prior to differentiation. However, these cells also express
high levels of MyoD, suggesting that the ratio of c-myc to
myogenic HLH family gene products is the crucial parame-
ter.
Myogenin is expressed in differentiated celis but not in
MT-myc/MyoDl cells inhibited from differentiating. Mecha-
nisms that may rely on quantitative relationships among
HLH molecules must also accommodate additional family
members that may ultimately participate in MyoD-initiated
myogenesis. To further characterize the repertoire of HLH
muscle regulators in these cells, we performed RNase pro-
tection experiments by using mouse Myf-5 and herculin
probes (37), and no expression was detected even after long
autoradiographic exposures (data not shown). However, a
similar experiment using a mouse myogenin probe (Fig. 4)
shows that myogenin is expressed when cells differentiate
(lanes 3, 5, and 9 through 12) but not when cells are
proliferating (lanes 1, 2, 7, and 8) or are inhibited from
differentiating (lanes 4 and 6). Myogenin is the only member
of the MyoD family that has been detected in all differenti-
ated skeletal muscle cell lines examined to date (5, 37, 39).
Consistent with the hypothesis that myogenin has an impor-
tant function in the differentiation decision, this experiment
shows that when c-myc is induced, myogenin expression
fails to be activated.
Can myogenin or MyoD-myogenin coexpression bypass the
inhibitory effects of myc? The observation that up-regulation
of myogenin and subsequent myogenic differentiation are
inhibited by elevated c-myc levels led us to hypothesize that
the inhibitory effect of c-myc might be bypassed if both
myogenin and MyoD were provided. Furthermore, two facts
suggested that both myogenic regulators should be required
for such a bypass. First, observations of diverse skeletal
muscle myocytes lead to a generalization that they always
coexpress myogenin and at least one additional HLH myo-
genic regulator (5, 37, 39). Second, BC3H1 myoblasts are
efficiently inhibited from differentiating in the presence of
myogenin-specific antisense oligonucleotides (10) even
though they express Myf-5 (5, 39). Thus, in NIH 3T3 cells,
perhaps both myogenin and MyoD are needed for activation
of differentiation-specific genes, and only if both are pro-
vided can c-myc inhibition be relieved.
Since c-myc had already been shown to inhibit myogenesis
in transient cotransfection assays with MyoD (Fig. 1), a
similar experiment was done to test whether myc would
suppress differentiation initiated by myogenin. The rat myo-
genin cDNA (59) was inserted into the pECE vector, and
NIH 3T3 cells were transfected with the mixtures indicated
in Fig. 5. The amount of myc plasmid used was one-half the
total molar amount of myogenic plasmid. After 3 days in
differentiation medium, cells were fixed and immunostained
for MHC, and differentiated cells were counted. The results
show that MyoD and myogenin act cooperatively when
transfected together, in that they convert significantly more
NIH 3T3 cells to myocytes than do the same molar doses of
myogenin or MyoD alone (cf., reference 49). Nevertheless,
c-myc inhibited differentiation whether MyoD, myogenin, or
a mixture of the two was used to initiate myogenesis. Thus,
although the activation of myogenin that normally accompa-
nies differentiation of MyoDl cells is suppressed by c-myc,
myogenin provided ectopically cannot relieve the overall
inhibition of differentiation. The straightforward interpreta-
MOL. CELL. BIOL.
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FIG. 6. Ribonuclease protection assays for Id RNA. The RNA
samples from Fig. 3 were assayed for expression of Id, an inhibitor
of differentiation. The results show that Id expression is properly
down-regulated even in cells exhibiting c-myc-dependent suppres-
sion of differentiation (lanes 4 and 6). The amount ofRNA used was
5 ,ug for each lane.
similar in their expression patterns under growth factor-rich
and -poor conditions (Fig. 7A), we have detected no altera-
tion in Id levels in response to ectopic c-myc.
Transfection Mixture
FIG. 5. Transient cotransfection of myogenin, alone or with
MyoD, cannot bypass c-myc inhibition of myogenesis. NIH 3T3
cells were plated on 6-cm-diameter dishes. Each transfection mix-
ture was divided among three dishes and contained the molar
equivalent of 20 pg of pSVclls as its myogenic component. Note that
the total molar amount of myogenic plasmid in each mixture of
MyoD and myogenin is equal to their molar amounts when used
individually. pSVmyc (9.1 ,ug) was sometimes included, as indi-
cated, which was half that molar amount. Otherwise, 6.2 pLg of
pECE was included to balance the total SV40 promoter content. The
transfection procedure was as described in Materials and Methods,
except that 70 ,uM chloroquine was added to the medium during the
first 6 h of transfection, after which the cells were rinsed with
DMEM, fed fresh medium, and then switched to differentiation
medium 24 h later for 3 days. After fixing and staining for MHC,
positive cells in 15 fields were counted at a 25x magnification. In
this experiment, the maximum was 670 differentiated cells counted.
Two repetitions of this experiment yielded similar qualitative re-
sults.
tion is that in these cells, MyoD and myogenin together may
be necessary for differentiation, but they are not sufficient to
force differentiation in the presence of c-myc.
Expression of Id is not influenced by ectopic c-myc levels and
is down-regulated even in cells inhibited from differentiating.
The pattern of expression of Id, a negative regulator of
MyoD-initiated muscle gene transcription (2), parallels the
pattern of endogenous c-myc expression during myogenesis.
Both are expressed at relatively high levels during prolifer-
ation compared with those expressed upon differentiation.
This raised the possibility of a hierarchical relationship
between the two in which elevated c-myc would exert its
phenotypic effect by driving expression of Id. Thus, in our
studies, myc might inhibit differentiation indirectly by posi-
tively regulating expression of Id in zinc-induced MT-mycl
MyoDl cells under mitogen-poor conditions, whereas Id
levels would be down-regulated in the absence of zinc
because of lower levels of c-myc. However, a direct exper-
imental test of this possibility found Id to be down-regulated
identically in the presence and absence of suppressing levels
of c-myc. Figure 6 shows that even in cells that are inhibited
from differentiating by c-myc (lanes 4 and 6), Id levels are no
higher than those in cells that have differentiated (lanes 3, 5,
and 9 through 12). Thus, while c-myc and Id are normally
DISCUSSION
c-myc is normally expressed in proliferating myoblasts
and is down-regulated upon differentiation into myocytes
(22, 51). We have begun to dissect the regulatory effects of
c-myc on myogenesis initiated by MyoD, myogenin, or a
combination of the two. In these experiments, expression of
c-myc has been uncoupled from environmental and cellular
factors which normally influence its regulation. The central
result is that preventing the drop in c-myc expression that
normally occurs at the onset of differentiation results in
inhibition of muscle differentiation.
Comparison of myc-mediated inhibition with effects of other
negative regulators. Our experiments suggest a significant
role for c-myc in the differentiation decision which differs
from the roles of other negative regulators tested in previous
studies. Earlier steps in myogenesis are affected by pertur-
bations in ras (32, 35, 43, 44, 53), proliferin (58), c-fos (35),
and perhaps src (24), all leading to suppression of muscle
differentiation, though there are conflicting results in some
systems (27). Mutant-activated ras and excessfos have been
shown to prevent or reduce transcription of the endogenous
MyoD gene (32, 35), and in one study activated ras-depen-
dent inhibition of myogenic differentiation was shown to be
accompanied by an up-regulation of c-myc RNA, even in
differentiation medium (43). Proliferin appears to act by
reducing the level of MyoD expression or by altering the
MyoD transcript, perhaps making it nonfunctional as MyoD
mRNA (58). In contrast to these examples of myogenic
inhibition, which act on regulation of MyoD, we have shown
that c-myc is able to inhibit differentiation in cell lines at a
more distal point in the regulatory pathway-even in the
presence of constitutive MyoD. However, while our use of
the NIH 3T3 cell line afforded experimental control ofMyoD
levels in the absence of endogenous MyoD expression, it
prevented us from determining whether c-myc, like activated
ras and fos, can down-regulate an active endogenous MyoD
gene. A further observation in our study is that the c-myc
inhibition of cellular differentiation cannot be overcome by
expression of myogenin, alone or in conjunction with MyoD.
By contrast, in the case of activated ras orfos, constitutive
MyoD from a stably transfected cDNA bypassed their
suppressing effects (32, 35).
While the present study shows that c-myc inhibits myo-
genic differentiation effectively in both transient and stable
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FIG. 7. (A) Expression patterns of genes involved in myogenic
determination and differentiation in cultured cell lines. The data
summarize expression patterns in naturally occurring skeletal mus-
cle cell lines; ectopic expression of any one of the four MyoD family
myogenic regulators by transfection can change these patterns.
References: MyoD (17), myogenin (20, 59), Myf-5 (5, 39), MRF4/
herculin (37, 47), E12/E47 (40), c-myc (51), Id (2), MHC, MCK, and
a-actins (48). a While many cell lines fuse into multinucleated
myotubes concurrent with biochemical differentiation, BC3H1 cells
do not; however, transfection of a MyoD expression vector into
these cells corrects the fusion defect (8). b While we find that
differentiated C2C12 cells express all four myogenic regulators,
many cell lines express only myogenin and either MyoD (e.g.,
MM14 cells) or Myf-5 (e.g., BC3H1 cells) but not both. c Although
we have detected myogenin RNA in nominally proliferating MM14
and C2C12 cells (37, 39), this is presumed to be contributed by
spontaneously differentiated cells, which are frequently found in
those cultures even in the presence of high levels of growth factors.
d We detect herculin in differentiated C2C12 cells (37) and at much
lower levels in both proliferating and differentiated BC3H1 cells
(36a); low level expression of MRF4 (the herculin homolog in rats)
has been reported in differentiated L6 cells (47) and in L8 cells (6).
Otherwise, while herculin is abundantly expressed in adult mouse
skeletal muscle tissue, it is rarely expressed in cultured cell lines.
However, myf-6 (the herculin homolog in humans) is expressed in
primary human myocytes in culture (6). (B) A speculative model for
a myogenic regulatory network. Arrows represent activation, loops
represent autoregulation, bars represent inhibition, and curves
represent cooperative activation. E12 is meant to be representative
of the several known daughterless homologs which can hetero-
oligomerize with the MyoD family members.
transfection formats, the situation for ras and fos is more
complicated. Their inhibitory effects can be bypassed by
stable transfection with a MyoD expression vector, yet they
cannot be bypassed when transiently cotransfected with
MyoD and a muscle-specific chloramphenicol acetyltransfer-
ase reporter gene into C3H 1OT1/2 cells (35). In that report
(35), it was suggested that the negative activities of ras and
fos dominate over the positive activities of MyoD in a
transient assay but not in stable cell lines because the former
may allow for a higher ratio of oncogene-to-MyoD activity.
In addition, it is not certain what, if any, contribution is
made to total MyoD levels by the endogenous gene in the
transients (cf., reference 54), nor is it known whether
myogenin is expressed or whether c-myc is up-regulated (as
in reference 43). Whatever the explanation for the differ-
ences observed in the two assays, the results show that
activated ras or excess fos may also act at a step later than
MyoD expression, as c-myc clearly does.
Mechanisms of c-myc action. What are the possible mech-
anisms for c-myc inhibition of muscle differentiation? c-myc
is localized in nuclei and contains motifs characteristic of
sequence-specific DNA-binding proteins, including the
B-HLH motif, essential for oligomerization and function of
MyoD family regulators (16, 41), and a leucine zipper, a
motif known to function in dimerization of other transcrip-
tion factors such as fos and jun (33). These characteristics
suggest two direct mechanisms for myogenic inhibition. In
one, myc would bind to promoters or enhancers of down-
stream muscle-specific genes and act as a repressor. An
alternative direct mechanism would have myc inactivate
positive-acting muscle-specific transcription factors of the
MyoD type by binding to them or to an essential limiting
partner. Indeed, the apparent sensitivity of c-myc inhibition
to the myc-to-MyoD ratio (shown in this study) is consistent
with such a titration by c-myc. However, attempts to
achieve dimerization of c-myc with these (or other) potential
partners in standard in vitro assays have thus far failed (31).
Moreover, strong evidence supporting sequence-specific
DNA binding for myc is also lacking, though myc does have
a general affinity for DNA (19, 45). Nevertheless, the initial
negative results of such in vitro studies do not convincingly
rule out the mechanisms outlined above.
Less direct mechanisms to explain c-myc effects on differ-
entiation must also be considered. c-myc was first identified
as an oncogene, thereby implicating it in the control of cell
proliferation. More recent studies assign c-myc a significant
role in regulating entry into G1 and S phases of the cell cycle
(11). This is relevant to skeletal myogenesis because it is well
established that the permissive point in the cell cycle for the
onset of differentiation is the Go-G1 boundary (13). Thus,
since c-myc can drive a subset of quiescent NIH 3T3 cells
out of Go and into G1 and S phases, its ability to inhibit
differentiation may be secondary to its ability to activate
genes involved in progression through the cell cycle. Argu-
ing against this view are two observations. (i) Up to 75% of
MT-myc/MyoDl cells differentiated in some of our experi-
ments, and the extent of inhibition by c-myc induction
exceeded 80%o, thus involving a far larger fraction of MT-
myc cells than can ever be forced into S phase by a myc
induction, which is -30% (36b). (ii) Although progression
into S phase does not appear to fully explain the observed
phenotype, a myc-mediated progression into a position in G1
which is prohibitive for differentiation is possible. While
definitive studies will require isolation and use of markers
that subdivide progress into and through G1, our data
showing a lack of Id expression characteristic of cycling cells
(Fig. 6) also argue against a mechanism dependent on
cycling.
Positive and negative regulatory pathways of myogenesis in
cultured cell lines. Figure 7A summarizes the expression
patterns of positively and negatively acting myogenic regu-
latory genes in cell lines in culture and includes the expres-
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sion pattern of some mature muscle markers. These data
provide the biological context for a simple speculative model
based upon the observations in this paper together with prior
studies (Fig. 7B). It accommodates the effects of the posi-
tive- and negative-acting regulators presently known and
integrates data from naturally occurring myogenic cell lines
as well as transfection-initiated myoblast lines. The first step
identified is determination, the transition from a multipoten-
tial stem cell to a myoblast. Here it is accomplished by
expression of MyoD, although in other instances Myf-5
might substitute at this step. As indicated, MyoD is some-
times (but not always) able to establish an autoregulatory
loop (55). The initial trigger of MyoD expression is presently
unknown, but one plausible candidate is the genetically
defined myd locus, which has been shown to activate MyoD
when transfected into nonmyogenic cells (46). The ski onco-
gene, which can also convert fibroblasts to myoblasts in
transfection assays (15), may also be involved. Negative
regulators that act by disrupting MyoD expression include
activated ras, excess c-fos, and proliferin, and they appear
to be able to function even after the MyoD autoregulatory
loop has been established (32, 35, 58). c-myc and Id have not
yet been formally tested for a similar negative effect on
MyoD expression in proliferating myoblasts. However, un-
der growth factor-rich conditions that support proliferation
of MyoD-positive myoblasts, significant levels of both c-myc
and Id have been found in all cases, and we therefore think
it is very likely that their expression is compatible with
expression of MyoD.
At the next step in the pathway, MyoD-positive myoblasts
are signalled to differentiate, which is accomplished in vitro
by removing serum growth factors. A rapid response to
reduced growth factors is a drop in Id and c-myc expression.
One expected result will be the release of any B-HLH
proteins that were previously nonfunctional because of
sequestration by Id through protein-protein interactions.
Indeed, E12 and MyoD both bind efficiently to Id in vitro,
and this association inactivates their DNA-binding capaci-
ties. These observations led Benezra et al. (2) to propose
that a MyoD/E12 hetero-oligomer is necessary for the onset
of differentiation, and this activation step is indicated as the
early phase of differentiation in Fig. 7B. Within the resolu-
tion of our kinetic measurements, myogenin expression
begins concurrent with the drop in Id and c-myc; myogenin
then appears to be able to positively autoregulate (5, 20).
Experiments presented here and by Benezra et al. (2)
indicate that this kinetically early step in differentiation
(relative to MHC and MCK expression) is inhibited by c-myc
and Id. Additionally, Lassar et al. (35) provide evidence that
high levels of mutant ras orfos relative to MyoD also inhibit
the myogenin activation step, and the results of Olson et al.
(43) suggest that such inhibition by activated ras may actu-
ally be mediated by up-regulation of c-myc expression. Since
myogenin has been found to be expressed in all differenti-
ating myogenic cell lines examined (5, 37, 39), this step may
be essential for differentiation. Direct support for this comes
from studies which show that BC3H1 and L6-A1 myoblasts
are efficiently inhibited from differentiating in the presence
of myogenin-specific antisense oligonucleotides (10, 25).
As differentiation proceeds, muscle-specific genes such as
those encoding MHC and MCK are transcribed, and in some
cases, cell fusion occurs to produce terminally differentiated
myotubes. As E12 can dimerize with myogenin (9) as well as
with MyoD (2, 41) and can bind to essential cis-acting
elements in muscle-specific enhancers, both myogenin-E12
and MyoD-E12 complexes are good candidates for playing a
central role in transcriptional activation of terminal differen-
tiation genes. This final step in Fig. 7B is responsive to
inhibition by ectopic c-myc expression, as demonstrated in
our cotransfections using c-myc, myogenin, and MyoD. Id
has not yet been formally tested for its ability to inhibit
similarly in the presence of MyoD and myogenin. However,
the molecular data showing that Id can inactivate E12 in
vitro (2) suggest that ectopic Id expression will also block the
final step of differentiation.
The group of positive and negative myogenic regulatory
factors presented in Fig. 7 have been identified as such
primarily by testing their activities in cultured cell lines and
in in vitro biochemical studies. The repertoire of regulators
described thus far is probably incomplete, but among those
currently known some redundancy in both positive and
negative regulators is already apparent. For example, all
four MyoD family regulators can convert some nonmyogenic
cells to myoblasts, yet some cell lines differentiate efficiently
without expression of Myf-5 or herculin, while others can
proceed without MyoD. Additionally, our results suggest
that c-myc and Id can act independently as negative regula-
tors. This leads to the prediction that even if Id expression is
eliminated in myoblasts cultured in growth factor-rich me-
dium, such myoblasts will not spontaneously differentiate
because c-myc would provide an independent negative con-
trol (unless Id positively regulates c-myc activity-a testable
possibility). Conversely, elimination of c-myc expression
should not allow for differentiation if Id expression is main-
tained. Therefore, the minimal requirement for premature
activation of muscle-specific genes in myoblasts would be
the inactivation of both c-myc and Id.
The existence of at least two independent negative regu-
lators of muscle differentiation may be useful to the organ-
ism, because such redundancy would ensure that differenti-
ation does not occur before myoblasts have migrated to their
proper locations in the developing embryo and have prolif-
erated sufficiently to properly fill their compartments. Be-
cause of its positive effects on progression through the cell
cycle and its negative effects on differentiation, c-myc ap-
pears well suited as a physiological regulator that simulta-
neously prevents premature differentiation and promotes
expansion of precursor cell numbers in lineages where
linkage of these activities is important.
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